-
Mashup Score: 1Should Induction Chemoimmunotherapy Lead Us to Broaden Our Definition of Resectability in NSCLC? - 7 month(s) ago
Dr. Howard (Jack) West explores the question of whether the prevailing standard of care in resectable NSCLC should change so that surgery becomes the routine recommendation for patients beyond the upper limit of what has historically been considered as surgical disease.
Source: dailynews.ascopubs.orgCategories: Latest Headlines, Partners & KOLsTweet
-
Mashup Score: 0Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17 - 7 month(s) ago
PURPOSE The integration of immunotherapy in the perioperative setting of muscle-invasive urothelial carcinoma (MIUC) appears promising. SAKK 06/17 investigated the addition of neoadjuvant durvalumab to gemcitabine/cisplatin (GC) chemotherapy followed by radical surgery and adjuvant checkpoint inhibition with durvalumab. PATIENTS AND METHODS SAKK 06/17 was an investigator-initiated, open-label, single-arm phase II study including cisplatin-fit patients with stage cT2-T4a cN0-1 operable MIUC. Four cycles of neoadjuvant GC in combination with four cycles of durvalumab (start with GC cycle 2) were administered, followed by radical surgery. Adjuvant durvalumab was given for 10 cycles. The primary end point was event-free survival (EFS) at 2 years. RESULTS Sixty one patients were accrued at 12 sites. The full analysis set consisted of 57 patients, 54 (95%) had bladder cancer. Median follow-up was 40 months. The primary end point was met, with EFS at 2 years of 76% (one-sided 90% CI [lower bo
Source: ascopubs.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0article - 7 month(s) ago
INTRODUCTIONMantle cell lymphoma (MCL) is a B-cell malignancy mainly diagnosed in the elderly population, and more commonly among males. It is among the more recently defined forms of B-cell lymphomas, when the association between centrocytic morphology and the presence of a translocation t(11;14) was made in the 1990s,1 defining what is now classified as MCL.Since then, the lymphoma community…
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Intratumoral Microbiota Composition Regulates Chemoimmunotherapy Response in Esophageal Squamous Cell Carcinoma - 7 month(s) ago
Analysis of intratumoral microbiota in patients with esophageal cancer identifies a microbiota signature that is associated with chemoimmunotherapy response and reveals that Streptococcus induces a favorable response by stimulating CD8+ T-cell infiltration.
Source: aacrjournals.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 5What We Have Learned About Combining a Ketogenic Diet and Chemoimmunotherapy: A Case Report and Review of Literature - 8 month(s) ago
Background: A high-fat, moderate-protein, low-carbohydrate ketogenic diet has been reported in the literature as a treatment option for patients with cancer.Case Presentation: A 69-year-old veteran was initially diagnosed with stage III colorectal cancer and progressed to having liver, pancreatic, and omental lymph node involvement despite completing adjuvant FOLFOX (fluorouracil, leucovorin calcium, and oxaliplatin) after surgery. The patient was treated with FOLFIRI (fluorouracil, leucovorin calcium, and irinotecan hydrochloride) and bevacizumab, followed by encorafenib and cetuximab on progression. Subsequently, he received pembrolizumab but continued to progress. The patient was later placed on trifluridine/tipiracil and bevacizumab concurrent with a ketogenic diet. Positron emission tomography and carcinoembryonic antigen levels indicated disease stabilization for 10 months. On progression, the patient was transitioned to ipilumimab and nivolumab and continued to adhere to the ket
Source: www.mdedge.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#Keto diet's impact on cancer treatment #MedTwitter #Chemoimmunotherapy https://t.co/8LQLkx3wSl https://t.co/mGxmbsClKh
-
-
Mashup Score: 0Potential Role for Chemoimmunotherapy in the 2L Setting of PD-L1–High Advanced NSCLC - 1 year(s) ago
Centering focus on the second-line setting of PD-L1–high metastatic NSCLC, a key opinion leader defines a potential role for chemoimmunotherapy,
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Chemoimmunotherapy Yields Promising Objective Responses in Patients With High-Risk Neuroblastoma - 2 year(s) ago
Among 71 patients with neuroblastoma, 48.6% achieved an objective response and 29% achieved a complete response with a 4-drug combination.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 6JNCCN 360 - B-Cell Lymphomas - Overcoming Resistance to TP53-Mediated Chemoimmunotherapy in B-Cell Malignancies - 2 year(s) ago
By: Julia Fiederlein Posted: Thursday, September 29, 2022 Loss of TP53 leads to increased PD-L1 expression and extracellular vesicle formation from B-cell lymphoma cells, according to Elena Izquierdo, PhD, of the Center for Integrated Oncology, Cologne, Germany, and colleagues. The results of a recent study, which were…
Source: jnccn360.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0JNCCN 360 - B-Cell Lymphomas - Overcoming Resistance to TP53-Mediated Chemoimmunotherapy in B-Cell Malignancies - 2 year(s) ago
By: Julia Fiederlein Posted: Thursday, September 29, 2022 Loss of TP53 leads to increased PD-L1 expression and extracellular vesicle formation from B-cell lymphoma cells, according to Elena Izquierdo, PhD, of the Center for Integrated Oncology, Cologne, Germany, and colleagues. The results of a recent study, which were…
Source: jnccn360.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2JNCCN 360 - CLL - Long-Term Outcomes With Chemoimmunotherapy Regimen in IGHV-Mutated CLL - 2 year(s) ago
By: Julia Fiederlein Posted: Tuesday, August 9, 2022 Nitin Jain, MD, of The University of Texas MD Anderson Cancer Center, Houston, and colleagues conducted a phase II trial to investigate the role of ibrutinib plus fludarabine, cyclophosphamide, and obinutuzumab (FCG) in previously untreated patients with IGHV-mutated…
Source: jnccn360.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @JNCCN: Long-Term Outcomes With #Chemoimmunotherapy Regimen in IGHV-Mutated #CLL: https://t.co/twgEcqPReL #JNCCN360 #immunotherapy #leu…
-
Should induction #chemoimmunotherapy lead us to broaden our definition of resectability in #NSCLC? @JackWestMD provides his insights in the latest #ASCODailyNews editorial: https://t.co/LFVPcxyb6I #lungcancer #lcsm https://t.co/FMlmrdLAH5